Literature DB >> 1693666

Identification of B epitopes in human papillomavirus type 16 E7 open reading frame protein.

R W Tindle1, J A Smith, H M Geysen, L A Selvey, I H Frazer.   

Abstract

Human papillomavirus (HPV) type 16 is implicated in the aetiology of anogenital dysplasia which may progress to malignancy. HPV-16 DNA is actively transcribed in cervical carcinomas, the most abundant transcripts being from the E6 and E7 early open reading frames. The E7 protein has been shown to have transforming activity in vitro. In this report we define four immunodominant B epitopes within the protein corresponding to the E7 gene, using a panel of murine monoclonal antibodies. Three epitopes are linear and lie within the N-terminal region of the molecule, and are unique to the HPV-16 E7 protein. One epitope is non-linear and presumed to be conformational. At least three of the four epitopes of the E7 protein are detectable by immunoprecipitation from an HPV-16-infected cervical carcinoma cell line. The demonstrated immunogenicity of the E7 protein allows us to deduce that this molecule may be a potential candidate for incorporation in a vaccine against cervical cancer.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1693666     DOI: 10.1099/0022-1317-71-6-1347

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  15 in total

1.  Human papillomavirus type 18 E6 and E7 antibodies in human sera: increased anti-E7 prevalence in cervical cancer patients.

Authors:  C Bleul; M Müller; R Frank; H Gausepohl; U Koldovsky; H N Mgaya; J Luande; M Pawlita; J ter Meulen; R Viscidi
Journal:  J Clin Microbiol       Date:  1991-08       Impact factor: 5.948

2.  Human papillomavirus 16 E7 protein is associated with the nuclear matrix.

Authors:  I Greenfield; J Nickerson; S Penman; M Stanley
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-15       Impact factor: 11.205

3.  A "public" T-helper epitope of the E7 transforming protein of human papillomavirus 16 provides cognate help for several E7 B-cell epitopes from cervical cancer-associated human papillomavirus genotypes.

Authors:  R W Tindle; G J Fernando; J C Sterling; I H Frazer
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-01       Impact factor: 11.205

4.  Identification of T- and B-cell epitopes of the E7 protein of human papillomavirus type 16.

Authors:  S A Comerford; D J McCance; G Dougan; J P Tite
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

5.  Characterization of human antibody-reactive epitopes encoded by human papillomavirus types 16 and 18.

Authors:  S A Jenison; X P Yu; J M Valentine; D A Galloway
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

6.  A vaccine conjugate of 'ISCAR' immunocarrier and peptide epitopes of the E7 cervical cancer-associated protein of human papillomavirus type 16 elicits specific Th1- and Th2-type responses in immunized mice in the absence of oil-based adjuvants.

Authors:  R W Tindle; S Croft; K Herd; K Malcolm; A F Geczy; T Stewart; G J Fernando
Journal:  Clin Exp Immunol       Date:  1995-08       Impact factor: 4.330

Review 7.  Pathogenesis of genital HPV infection.

Authors:  A Schneider
Journal:  Genitourin Med       Date:  1993-06

Review 8.  Pathobiology of papillomavirus-related cervical diseases: prospects for immunodiagnosis.

Authors:  C P Crum; S Barber; J K Roche
Journal:  Clin Microbiol Rev       Date:  1991-07       Impact factor: 26.132

9.  Anti-sense phosphorothioate oligonucleotides have both specific and non-specific effects on cells containing human papillomavirus type 16.

Authors:  A Storey; D Oates; L Banks; L Crawford; T Crook
Journal:  Nucleic Acids Res       Date:  1991-08-11       Impact factor: 16.971

10.  Minute time scale prolyl isomerization governs antibody recognition of an intrinsically disordered immunodominant epitope.

Authors:  Marisol Fassolari; Lucia B Chemes; Mariana Gallo; Clara Smal; Ignacio E Sánchez; Gonzalo de Prat-Gay
Journal:  J Biol Chem       Date:  2013-03-15       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.